Misplaced Pages

Rachel Haurwitz: Difference between revisions

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively← Previous editContent deleted Content addedVisualWikitext
Revision as of 03:24, 11 November 2019 editPatapsco913 (talk | contribs)Autopatrolled, Extended confirmed users166,995 edits →Early life and education← Previous edit Latest revision as of 10:01, 31 December 2024 edit undoWilliam Avery (talk | contribs)Autopatrolled, Extended confirmed users, Page movers, Pending changes reviewers, Rollbackers476,401 edits MOS:GEOLINK 
(31 intermediate revisions by 19 users not shown)
Line 1: Line 1:
{{Short description|American biochemist (born 1985)}}
{{Use American English|date=September 2018}} {{Use mdy dates|date=September 2018}} {{Use American English|date=September 2018}} {{Use mdy dates|date=September 2018}}
{{Infobox scientist {{Infobox scientist
| name = Rachel Haurwitz | name = Rachel Haurwitz
| image = Rachel Haurwitz 2019.jpg | image = Rachel Haurwitz 2019.jpg
| image_size = | image_size =
| alt = | alt =
| caption = | caption = Haurwitz in 2019
| birth_name = Rachel Elizabeth Haurwitz | birth_name = Rachel Elizabeth Haurwitz
| birth_date = {{Birth date and age|mf=yes|1985|05|20}} | birth_date = {{Birth date and age|mf=yes|1985|05|20}}
| birth_place = ], ], U.S. | birth_place = ], U.S.
| death_date = <!-- {{Death date and age|YYYY|MM|DD|YYYY|MM|DD}} (death date then birth date) --> | death_date = <!-- {{Death date and age|YYYY|MM|DD|YYYY|MM|DD}} (death date then birth date) -->
| death_place = | death_place =
| fields = ] | fields = ]
| workplaces = Caribou Biosciences | workplaces = Caribou Biosciences
| alma_mater = {{Plainlist| | alma_mater = {{Plainlist|
* ] (B.A.) * ] (B.A.)
* ] (Ph.D.)}} * ] (Ph.D.)}}
| thesis_title = The CRISPR endoribonuclease Csy4 utilizes unusual sequence- and structure-specific mechanisms to recognize and process crRNAs | thesis_title = The CRISPR endoribonuclease Csy4 utilizes unusual sequence- and structure-specific mechanisms to recognize and process crRNAs
| thesis_url = https://escholarship.org/uc/item/0rh5940p | thesis_url = https://escholarship.org/uc/item/0rh5940p
| thesis_year = 2012 | thesis_year = 2012
| doctoral_advisor = ] | doctoral_advisor = ]
| academic_advisors = ] | academic_advisors =
| doctoral_students = | doctoral_students =
| notable_students = | notable_students =
| known_for = | known_for =
}} }}
'''Rachel Elizabeth Haurwitz''' (born May 20, 1985) is an American biochemist and structural biologist. She is the co-founder, chief executive officer, and president of Caribou Biosciences, a ] company. '''Rachel Elizabeth Haurwitz''' (born May 20, 1985) is an American biochemist and structural biologist. She is the co-founder, chief executive officer, and president of Caribou Biosciences, a ] company.


== Early life and education == == Early life and education ==
Haurwitz was born to a ] family on May 20, 1985.<ref name=":0">{{Cite news|url=https://www.haaretz.com/us-news/jewish-insider-s-daily-kickoff-may-18-2018-1.6097852|title=Jewish Insider's Daily Kickoff: May 18, 2018|date=2018-05-18|work=]|access-date=2018-09-05|language=en}}</ref> She grew up in ], ]. Her mother is elementary school teacher and her father, an environmental journalist. She self describes her younger self as "your average science nerd." While in high school, Haurwitz kept 400 '']'' in the family's dining room to conduct ] experiments.<ref name=":1">{{Cite news|url=https://www.ozy.com/rising-stars/this-scientist-turned-ceo-wants-to-gene-edit-a-way-to-cure-cancer/85243#.WrBcvXemsnU.twitter|title=This Scientist Turned CEO Wants to Gene-Edit a Way to Cure Cancer|last=Fosco|first=Molly|date=2018-03-16|work=OZY|access-date=2018-09-05|language=en}}</ref> Haurwitz was born on May 20, 1985.{{citation needed|date=December 2019}} She grew up in ].<ref>{{Cite web |last1=Kincaid |first1=Ellie |last2=Tindera |first2=Michela |date=May 14, 2019 |title=Gene Hackers: The Young Biotech Entrepreneurs Looking To Make Billions By Editing Life Itself |url=https://www.forbes.com/sites/michelatindera/2019/05/14/crispr-biotech-biosciences/ |work=Forbes}}</ref> Her mother is an elementary school teacher and her father, an environmental journalist.<ref name=":1">{{Cite news|url=https://www.ozy.com/rising-stars/this-scientist-turned-ceo-wants-to-gene-edit-a-way-to-cure-cancer/85243#.WrBcvXemsnU.twitter|title=This Scientist Turned CEO Wants to Gene-Edit a Way to Cure Cancer|last=Fosco|first=Molly|date=2018-03-16|work=OZY|access-date=2018-09-05|language=en}}</ref>


Haurwitz began researching RNA during her undergraduate years.<ref>{{Cite news|url=https://www.statnews.com/2016/06/22/rachel-haurwitz-crispr-caribou/|title=For biotech CEO Rachel Haurwitz, CRISPR is big business|last=Herman|first=Elizabeth D.|date=2016-06-22|work=STAT|access-date=2018-09-05|language=en-US}}</ref> She attended ] where she earned an undergraduate degree. In 2007, she began doctoral studies at ]. At the age of 21,<ref>{{Cite news|url=https://mpnforum.com/the-two-faces-of-rachel-haurwitz/|title=The two faces of Rachel Haurwitz|last=|first=|date=2015-04-09|work=MPNforum Magazine|access-date=2018-09-05|language=en-US}}</ref> Haurwitz began working as a graduate student in ]'s laboratory, in 2008 where she completed her doctorate in molecular and cell biology.<ref name=":2">{{Cite news|url=https://techcrunch.com/2018/09/04/these-two-crispr-experts-are-coming-to-disrupt-sf-2018/|title=These two CRISPR experts are coming to Disrupt SF 2018|last=Buhr|first=Sarah|date=2018-09-04|work=TechCrunch|access-date=2018-09-05|language=en-US}}</ref> Haurwitz originally intended on becoming an intellectual property lawyer for biotechnology patents but later chose to continue pursuing science.<ref name=":3">{{Cite news|url=http://fortune.com/40-under-40/2016/rachel-haurwitz-23/|title=40 Under 40|last=|first=|date=2016-09-22|work=Fortune|access-date=2018-09-05|language=en-US}}</ref> Haurwitz began researching RNA during her undergraduate years.<ref>{{Cite news|url=https://www.statnews.com/2016/06/22/rachel-haurwitz-crispr-caribou/|title=For biotech CEO Rachel Haurwitz, CRISPR is big business|last=Herman|first=Elizabeth D.|date=2016-06-22|work=STAT|access-date=2018-09-05|language=en-US}}</ref> She attended ] where she earned an undergraduate degree. In 2007, she began doctoral studies at ]. At the age of 21,<ref>{{Cite news|url=https://mpnforum.com/the-two-faces-of-rachel-haurwitz/|title=The two faces of Rachel Haurwitz|date=2015-04-09|work=MPNforum Magazine|access-date=2018-09-05|language=en-US}}</ref> Haurwitz began working as a graduate student in ]'s laboratory, in 2008 where she completed her doctorate in molecular and cell biology.<ref name=":2">{{Cite news|url=https://techcrunch.com/2018/09/04/these-two-crispr-experts-are-coming-to-disrupt-sf-2018/|title=These two CRISPR experts are coming to Disrupt SF 2018|last=Buhr|first=Sarah|date=2018-09-04|work=TechCrunch|access-date=2018-09-05|language=en-US}}</ref> Haurwitz originally intended on becoming an intellectual property lawyer for biotechnology patents but later chose to continue in science.<ref name=":3">{{Cite news|url=http://fortune.com/40-under-40/2016/rachel-haurwitz-23/|title=40 Under 40|date=2016-09-22|work=Fortune|access-date=2018-09-05|language=en-US}}</ref>


== Career == == Career ==
In 2011, Haurwitz and Doudna co-founded '''Caribou Biosciences''', a gene editing ]-].<ref>{{Cite news|url=https://www.forbes.com/profile/rachel-haurwitz/?list=30under30-all-star-alumni#520109fc3c08|title=Rachel Haurwitz|work=Forbes|access-date=2018-09-05|language=en}}</ref> Haurwitz is the company's CEO and president. She holds several patents for CRISPR-based technologies.<ref name=":2" /> Caribou Biosciences was initially housed in the basement of the same building that housed Doudna's laboratory. Haurwitz's company supports the commercialization<ref>{{Cite journal|last=Leeming|first=Jack|date=2018-04-05|title=How researchers are ensuring that their work has an impact|journal=Nature|language=EN|volume=556|issue=7699|pages=139–141|doi=10.1038/d41586-018-03925-8|pmid=29620739|issn=0028-0836}}</ref> of CRISPR technology in healthcare and agriculture.<ref name=":4">{{Cite news|url=https://www.newsweek.com/sponsored/women-future/nominee-rachel-haurwitz|title=NOMINEE: Rachel Haurwitz|last=|first=|date=2018-01-18|work=Newsweek|access-date=2018-09-05|language=en}}</ref> Its researchers explore issues in antimicrobial resistance, food scarcity, and vaccine shortages.<ref name=":4" /> The company licensed Berkeley's CRISPR patent and deals with agricultural and pharmaceutical companies and research firms.<ref>{{Cite news|url=https://www.technologyreview.com/lists/innovators-under-35/2017/entrepreneur/rachel-haurwitz/|title=One woman's ascent from lab rat to CEO of a CRISPR company|last=Regalado|first=Antonio|date=2017|work=MIT Technology Review|access-date=2018-09-05|language=en}}</ref> As of 2018 she oversees 46 employees. In 2018, Haurwitz announced that Caribou Biosciences was shifting focus on medicine and developing cancer therapies targeting microbes.<ref name=":1" /> In 2011, Haurwitz and Doudna co-founded Caribou Biosciences, a gene editing ]-].<ref>{{Cite news|url=https://www.forbes.com/profile/rachel-haurwitz/?list=30under30-all-star-alumni#520109fc3c08|title=Rachel Haurwitz|work=Forbes|access-date=2018-09-05|language=en}}</ref> Haurwitz is the company's CEO and president. She holds several patents for CRISPR-based technologies.<ref name=":2" /> The firm was initially housed in the basement of the building that housed Doudna's laboratory. The company supports the commercialization<ref>{{Cite journal|last=Leeming|first=Jack|date=2018-04-05|title=How researchers are ensuring that their work has an impact|journal=Nature|language=EN|volume=556|issue=7699|pages=139–141|doi=10.1038/d41586-018-03925-8|pmid=29620739|bibcode=2018Natur.556..139L|issn=0028-0836|doi-access=free}}</ref> of CRISPR technology in healthcare and agriculture.<ref name=":4">{{Cite news|url=https://www.newsweek.com/sponsored/women-future/nominee-rachel-haurwitz|title=NOMINEE: Rachel Haurwitz|date=2018-01-18|work=Newsweek|access-date=2018-09-05|language=en}}</ref> Its researchers explore issues in antimicrobial resistance, food scarcity, and vaccine shortages.<ref name=":4" /> The company licensed Berkeley's CRISPR patent and deals with agricultural and pharmaceutical companies and research firms.<ref>{{Cite news|url=https://www.technologyreview.com/lists/innovators-under-35/2017/entrepreneur/rachel-haurwitz/|title=One woman's ascent from lab rat to CEO of a CRISPR company|last=Regalado|first=Antonio|date=2017|work=MIT Technology Review|access-date=2018-09-05|language=en}}</ref> In 2018, Haurwitz announced that the firm was shifting focus on medicine and developing cancer therapies targeting microbes.<ref name=":1" />

On being a woman executive, Haurwitz reports that she has experienced situations where she was treated differently because of her gender. She also states that she more frequently felt underestimated because of her young age.<ref>{{Cite web|url=https://www.bizjournals.com/sanfrancisco/c/women-who-lead-in-life-sciences-2018/2942/rachel-haurwitz.html|title=Women who lead in life sciences|date=2018|website=San Francisco Business Times|publisher=Bizjournals|access-date=2018-09-05}}</ref>

== Awards and honors ==
* 2014 ]<ref>{{cite web|url=https://www.forbes.com/30-under-30-2017/all-star-alumni/ |title=30 Under 30 2017: All-Star Alumni |work=]}}</ref>
* April 2018 ] Next Generation Award<ref>{{cite web |url= https://www.awis.org/awis-announces-top-awards-for-stem-and-gender-equity-champions/ |title=Association for Women in Science Announces Top Awards for STEM and Gender Equity Champions |publisher=]}}</ref>
* November 2018 '']''' America's Top 50 Women In Tech<ref>{{cite web |url= https://www.forbes.com/profile/rachel-haurwitz/?list=top-tech-women-america |title= Rachel Haurwitz |work=]}}</ref>


== Personal life == == Personal life ==
She is a long-distance runner and is training for a marathon.<ref name=":4" /> Haurwitz knits as a hobby.<ref name=":3" /> She is a long-distance runner and is training for a marathon.<ref name=":4" /> Haurwitz knits as a hobby.<ref name=":3" />

== Recognition ==
In 2021, Haurwitz was selected as a Bloomberg New Economy Catalyst. As part of the program, she attended the annual New Economy Forum held in Singapore, and the Bloomberg New Economy Catalyst Retreat that same year.<ref>{{Cite news |title=The Bloomberg New Economy Catalyst List |language=en |work=Bloomberg.com |url=https://www.bloomberg.com/features/2021-new-economy-catalyst-list/ |access-date=2023-07-19}}</ref>


== Selected works == == Selected works ==
Line 49: Line 46:
=== Papers === === Papers ===


* {{Cite journal|last=Haurwitz|first=Rachel E.|last2=Jinek|first2=Martin|last3=Wiedenheft|first3=Blake|last4=Zhou|first4=Kaihong|last5=Doudna|first5=Jennifer A.|author-link5=Jennifer Doudna|date=2010-09-10|title=Sequence- and Structure-Specific RNA Processing by a CRISPR Endonuclease|journal=Science|language=en|volume=329|issue=5997|pages=1355–1358|doi=10.1126/science.1192272|pmid=20829488|pmc=3133607}} * {{Cite journal|last1=Haurwitz|first1=Rachel E.|last2=Jinek|first2=Martin|last3=Wiedenheft|first3=Blake|last4=Zhou|first4=Kaihong|last5=Doudna|first5=Jennifer A.|author-link5=Jennifer Doudna|date=2010-09-10|title=Sequence- and Structure-Specific RNA Processing by a CRISPR Endonuclease|journal=Science|language=en|volume=329|issue=5997|pages=1355–1358|doi=10.1126/science.1192272|pmid=20829488|pmc=3133607|bibcode=2010Sci...329.1355H}}
* {{Cite journal|last=Qi|first=Lei|last2=Haurwitz|first2=Rachel E|last3=Shao|first3=Wenjun|last4=Doudna|first4=Jennifer A|author-link4=Jennifer Doudna|last5=Arkin|first5=Adam P|date=2012-09-16|title=RNA processing enables predictable programming of gene expression|journal=Nature Biotechnology|language=En|volume=30|issue=10|pages=1002–1006|doi=10.1038/nbt.2355|pmid=22983090}} * {{Cite journal|last1=Qi|first1=Lei|last2=Haurwitz|first2=Rachel E|last3=Shao|first3=Wenjun|last4=Doudna|first4=Jennifer A|author-link4=Jennifer Doudna|last5=Arkin|first5=Adam P|date=2012-09-16|title=RNA processing enables predictable programming of gene expression|journal=Nature Biotechnology|language=En|volume=30|issue=10|pages=1002–1006|doi=10.1038/nbt.2355|pmid=22983090|s2cid=1333889}}


== References == == References ==
{{reflist}} {{reflist}}


==External links==
{{Portal bar|Biography|Technology|Medicine|Biology|Science|California}}
*{{Scopus}}


{{Authority control}} {{Authority control}}
Line 63: Line 61:
] ]
] ]
⚫ ]
] ]
] ]
] ]
] ]
Line 74: Line 71:
] ]
] ]
]
] ]
⚫ ]
⚫ ]
] ]
] ]
⚫ ]
⚫ ]
⚫ ]

Latest revision as of 10:01, 31 December 2024

American biochemist (born 1985)

Rachel Haurwitz
Haurwitz in 2019
BornRachel Elizabeth Haurwitz
(1985-05-20) May 20, 1985 (age 39)
Austin, Texas, U.S.
Alma mater
Scientific career
FieldsBiochemistry
InstitutionsCaribou Biosciences
ThesisThe CRISPR endoribonuclease Csy4 utilizes unusual sequence- and structure-specific mechanisms to recognize and process crRNAs (2012)
Doctoral advisorJennifer Doudna

Rachel Elizabeth Haurwitz (born May 20, 1985) is an American biochemist and structural biologist. She is the co-founder, chief executive officer, and president of Caribou Biosciences, a genome editing company.

Early life and education

Haurwitz was born on May 20, 1985. She grew up in Austin, Texas. Her mother is an elementary school teacher and her father, an environmental journalist.

Haurwitz began researching RNA during her undergraduate years. She attended Harvard College where she earned an undergraduate degree. In 2007, she began doctoral studies at University of California, Berkeley. At the age of 21, Haurwitz began working as a graduate student in Jennifer Doudna's laboratory, in 2008 where she completed her doctorate in molecular and cell biology. Haurwitz originally intended on becoming an intellectual property lawyer for biotechnology patents but later chose to continue in science.

Career

In 2011, Haurwitz and Doudna co-founded Caribou Biosciences, a gene editing spinout-startup company. Haurwitz is the company's CEO and president. She holds several patents for CRISPR-based technologies. The firm was initially housed in the basement of the building that housed Doudna's laboratory. The company supports the commercialization of CRISPR technology in healthcare and agriculture. Its researchers explore issues in antimicrobial resistance, food scarcity, and vaccine shortages. The company licensed Berkeley's CRISPR patent and deals with agricultural and pharmaceutical companies and research firms. In 2018, Haurwitz announced that the firm was shifting focus on medicine and developing cancer therapies targeting microbes.

Personal life

She is a long-distance runner and is training for a marathon. Haurwitz knits as a hobby.

Recognition

In 2021, Haurwitz was selected as a Bloomberg New Economy Catalyst. As part of the program, she attended the annual New Economy Forum held in Singapore, and the Bloomberg New Economy Catalyst Retreat that same year.

Selected works

Papers

References

  1. Kincaid, Ellie; Tindera, Michela (May 14, 2019). "Gene Hackers: The Young Biotech Entrepreneurs Looking To Make Billions By Editing Life Itself". Forbes.
  2. ^ Fosco, Molly (March 16, 2018). "This Scientist Turned CEO Wants to Gene-Edit a Way to Cure Cancer". OZY. Retrieved September 5, 2018.
  3. Herman, Elizabeth D. (June 22, 2016). "For biotech CEO Rachel Haurwitz, CRISPR is big business". STAT. Retrieved September 5, 2018.
  4. "The two faces of Rachel Haurwitz". MPNforum Magazine. April 9, 2015. Retrieved September 5, 2018.
  5. ^ Buhr, Sarah (September 4, 2018). "These two CRISPR experts are coming to Disrupt SF 2018". TechCrunch. Retrieved September 5, 2018.
  6. ^ "40 Under 40". Fortune. September 22, 2016. Retrieved September 5, 2018.
  7. "Rachel Haurwitz". Forbes. Retrieved September 5, 2018.
  8. Leeming, Jack (April 5, 2018). "How researchers are ensuring that their work has an impact". Nature. 556 (7699): 139–141. Bibcode:2018Natur.556..139L. doi:10.1038/d41586-018-03925-8. ISSN 0028-0836. PMID 29620739.
  9. ^ "NOMINEE: Rachel Haurwitz". Newsweek. January 18, 2018. Retrieved September 5, 2018.
  10. Regalado, Antonio (2017). "One woman's ascent from lab rat to CEO of a CRISPR company". MIT Technology Review. Retrieved September 5, 2018.
  11. "The Bloomberg New Economy Catalyst List". Bloomberg.com. Retrieved July 19, 2023.

External links

Categories: